コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ruct capable of functioning as a therapeutic cancer vaccine.
2 d the late-stage clinical trials of a breast cancer vaccine.
3 improve the efficacy of an experimental anti-cancer vaccine.
4 ial use of grp170-secreting tumor cells as a cancer vaccine.
5 erred in combination with high-dose IL-2 and cancer vaccine.
6 ld point the way to an effective therapeutic cancer vaccine.
7 mits or alters its efficacy as a therapeutic cancer vaccine.
8 UC1 may be a promising candidate as a breast cancer vaccine.
9 cells and IL-2 can augment the function of a cancer vaccine.
10 romising target candidates for a therapeutic cancer vaccine.
11 tive immunotherapy with Canvaxin therapeutic cancer vaccine.
12 reenergize ACT (ReACT) with a pathogen-based cancer vaccine.
13 n allogeneic whole-cell therapeutic prostate cancer vaccine.
14 duce the next generation of highly efficient cancer vaccines.
15 ials showing benefit to the patients revived cancer vaccines.
16 g adjuvant in the development of therapeutic cancer vaccines.
17 nsideration for designing safe and effective cancer vaccines.
18 Cs and substantially enhanced the effects of cancer vaccines.
19 (CTLs) underpins the success of therapeutic cancer vaccines.
20 hopefully ending the Kafkaesque futility of cancer vaccines.
21 he MAGE-3 ASCI has also revived the field of cancer vaccines.
22 rs and are promising targets for therapeutic cancer vaccines.
23 ule as an effective component of therapeutic cancer vaccines.
24 nologic and therapeutic activity of DC-based cancer vaccines.
25 ueling controversy over the utility of human cancer vaccines.
26 ations of this work for developing effective cancer vaccines.
27 ould be modulated to improve the response to cancer vaccines.
28 should be important for developing molecular cancer vaccines.
29 ion for the further development of efficient cancer vaccines.
30 are potential targets for the development of cancer vaccines.
31 ages over other antigen delivery systems for cancer vaccines.
32 y have direct implications for the design of cancer vaccines.
33 ld be tested in therapeutic combination with cancer vaccines.
34 at may have implications in designing future cancer vaccines.
35 expressing tumors and for the development of cancer vaccines.
36 xes have clinical significance as autologous cancer vaccines.
37 es essential for the therapeutic efficacy of cancer vaccines.
38 it an appropriate candidate to combine with cancer vaccines.
39 es for the development of safe and effective cancer vaccines.
40 were synthesized and screened as therapeutic cancer vaccines.
41 ble and possibly clinically useful DNA-based cancer vaccines.
42 observations are of value for the design of cancer vaccines.
43 to the development of effective therapeutic cancer vaccines.
44 nt candidates for the development of generic cancer vaccines.
45 immunosurveillance and improves responses to cancer vaccines.
46 surface antigens and hence, as multifaceted cancer vaccines.
47 le platform for the development of effective cancer vaccines.
48 and potentially tune the immune response to cancer vaccines.
49 Cs) has been proposed for the preparation of cancer vaccines.
50 It contributes greatly to the failure of cancer vaccines.
51 open an opportunity to improve the effect of cancer vaccines.
52 approach for the design of protein-targeted cancer vaccines.
53 cell surface antigens and, hence, as potent cancer vaccines.
54 vel approach to the rational design of human cancer vaccines.
55 tients as a basis for constructing effective cancer vaccines.
56 he antitumor immune response induced by many cancer vaccines.
57 ovide opportunities for developing effective cancer vaccines.
58 ther the toxicity or efficacy of therapeutic cancer vaccines.
59 de the design of next-generation therapeutic cancer vaccines.
60 immune tolerance limits the effectiveness of cancer vaccines.
61 erance may limit the efficacy of therapeutic cancer vaccines.
62 ties for the development of antigen-specific cancer vaccines.
63 an important consideration in the design of cancer vaccines.
64 in immunized patients by these or other anti-cancer vaccines.
65 ive vehicles for the delivery of therapeutic cancer vaccines.
66 st, have been the major focus of therapeutic cancer vaccines.
67 significant interest for the development of cancer vaccines.
68 an effective platform for the development of cancer vaccines.
69 e microenvironments that create barriers for cancer vaccines.
70 a powerful new adjuvant system for TAA-based cancer vaccines.
71 ryl lipid A (MPLA) to form novel therapeutic cancer vaccines.
72 s protein may serve as a rational target for cancer vaccines.
73 reater therapeutic efficacy of peptide-based cancer vaccines.
74 us improve the antitumor efficacy of current cancer vaccines.
75 ivated T cells and natural killer cells, and cancer vaccines.
76 tating the rational design of more effective cancer vaccines.
77 well as an immune target for development of cancer vaccines.
78 on, as DC-targeted adjuvants for intradermal cancer vaccines.
79 tion can greatly impact the effectiveness of cancer vaccines.
80 form to generate "off-the-shelf" therapeutic cancer vaccines.
81 f antibody therapy and usher in a new era of cancer vaccines.
82 s, and (c) muIFN-gamma might be an effective cancer vaccine adjuvant by virtue of its ability to augm
84 ies include antitumor monoclonal antibodies, cancer vaccines, adoptive transfer of ex vivo activated
85 ion, dramatically enhances the activity of a cancer vaccine against liver metastases but not metastas
86 instrumental to the development of the first cancer vaccines against cancers having an infectious eti
89 epitope represents a potential candidate for cancer vaccines aimed at generating both CD4(+) and CD8(
90 show genetic regulation of the response to a cancer vaccine and an unequal effect of removing CD25(hi
91 with a mechanistic understanding of ongoing cancer vaccine and cellular immunotherapy clinical trial
95 designed to enhance this capacity, including cancer vaccines and coinhibitory receptor blockade, have
96 cuss the immunological basis for therapeutic cancer vaccines and how the current understanding of den
97 se III human clinical trials as adjuvants to cancer vaccines and in combination with conventional che
98 human clinical trials as an adjuvant to anti-cancer vaccines and in combination with other therapies.
99 ic T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via ad
101 mmunotherapeutic strategy based on synthetic cancer vaccines and metabolic engineering of TACAs on tu
102 Y-SAR-35 is therefore a potential target for cancer vaccines and monoclonal antibody-based immunother
104 ression in the dendritic cells (DCs) used as cancer vaccines and to enhance their responsiveness to l
105 esults in a clinical trial for a therapeutic cancer vaccine, and the successful mass immunisation of
107 clinical application of currently available cancer vaccine approaches is based more on surrogate end
110 gh rates of objective clinical response when cancer vaccines are combined with chemotherapy in patien
118 tractive candidate adjuvants for therapeutic cancer vaccines as they can induce a balanced humoral an
119 1) is considered as a potential target for a cancer vaccine, as it is overexpressed in many malignant
120 e p373-382 is a candidate epitope for breast cancer vaccines, as it is processed by proteasomes and b
122 efore, an important candidate component of a cancer vaccine based on a TRT substrate and validates th
123 d therapeutic options for ER-negative breast cancers, vaccines based on CT-X antigens might prove to
124 alogue poly(I:C) is a promising adjuvant for cancer vaccines because it activates both dendritic cell
125 broad implications for many of the DC-based cancer vaccines being developed for clinical application
126 an important consideration in the design of cancer vaccines, but factors affecting selection are not
127 stic approach for the development of generic cancer vaccines, but the potential of this type of vacci
128 genic, we investigated whether a therapeutic cancer vaccine called Canvaxin (CancerVax Corporation, C
131 e sufficient data to support the notion that cancer vaccines can induce anti-tumor immune responses i
138 entially making it a more potent therapeutic cancer vaccine compared with existing MAGE-A3 protein an
139 binatorial use of CD40 and TLR agonists as a cancer vaccine, compared with monotherapy, elicits high
140 viously reported a clinical trial of a human cancer vaccine consisting of autologous tumor cells modi
141 this potential, we have developed cell-based cancer vaccines consisting of tumor cells expressing syn
142 urium-NY-ESO-1) was shown to be an efficient cancer vaccine construct in mice and to stimulate NY-ESO
143 ses induced by PROSTVAC-VF, a poxvirus-based cancer vaccine currently in phase III clinical trials.
145 peutic noncellular (vector-based or subunit) cancer vaccines, dendritic cell vaccines, engineered T c
146 of cognate CD4+ T cell help is important for cancer vaccine design and provides the rationale for a p
148 y may allow for the design of more effective cancer vaccines designed to activate and maintain specif
151 sing a DNA vaccine have implications for all cancer vaccines designed to induce and maintain antibody
152 therefore, have implications on the DC-based cancer vaccine designs and are relevant in the inquiry i
153 istance of tumor recurrences to conventional cancer vaccines despite small tumor size, an intact anti
154 is Ag and thus represents a prime target for cancer vaccines, despite infrequent natural occurrence o
155 most effective when used to prevent disease, cancer vaccine development has focused predominantly on
164 might soon enhance the efficacy of existing cancer vaccines directed against a variety of malignanci
165 s suggest that PD-1 blockade enhances breast cancer vaccine efficacy by altering both CD8 T cell and
166 f TLR adjuvants systemically boosts DC-based cancer vaccine efficacy, it could also increase toxicity
167 ression continues to be a major inhibitor of cancer vaccine efficacy, we examined in this study wheth
169 targeting Listeria monocytogenes (LM) with a cancer vaccine enhanced the antitumor effect of vaccine-
171 pe-enhanced peptide may serve as a candidate cancer vaccine for HLA-B7+ patients with alveolar rhabdo
174 ng rationale for combining immunotoxins with cancer vaccines for the treatment of patients with advan
176 usefulness of p53-derived peptides as future cancer vaccines, frequencies of wt p53(264-272) peptide-
179 ntigens and their application in therapeutic cancer vaccines has not yet resulted in a successful the
182 ells for priming adaptive immunity, DC-based cancer vaccines have been largely insufficient to effect
188 generated from the preclinical evaluation of cancer vaccines have resulted in the initiation of clini
190 e 1 and 2 trials of PANVAC, a poxviral-based cancer vaccine, have suggested clinical efficacy in some
191 by comparing microarrays of cellular breast cancer vaccines highly enriched for cells that induced b
193 tic approaches currently used in the clinic: cancer vaccines, immunostimulatory agents, adoptive T ce
194 been tested in previous clinical trials for cancer vaccine immunotherapy, yet resulted in limited th
196 lls (DC-TC) are currently being evaluated as cancer vaccines in preclinical models and human immuniza
197 be very useful in enhancing the efficacy of cancer vaccines in the face of tumor immune suppression.
199 bination of ATRA with two different types of cancer vaccines in two different tumor models significan
200 lts have implications for the development of cancer vaccines, in particular, and for the process of e
203 immunogenic tumors and, in combination with cancer vaccines, increases the rejection of poorly immun
208 The in vivo therapeutic efficacy of DC-based cancer vaccines is limited by suboptimal DC maturation p
209 The difficulty in developing prophylactic cancer vaccines is primarily due to the fact that tumor
212 nted by host-derived APC, their inclusion in cancer vaccines may enhance activation of tumor-reactive
215 ith adoptive T-cell therapies or therapeutic cancer vaccines, may prove to be more efficient in prolo
217 revention through chemoprevention agents and cancer vaccines offers significant promise for reducing
219 and suggest HERV-K as a possible target for cancer vaccines or immunotherapy against this highly agg
221 steria monocytogenes is being developed as a cancer vaccine platform because of its ability to induce
224 tly met with clinical success, and the first cancer vaccine received U.S. Food and Drug Administratio
225 istory of targeting embryonal tissues toward cancer vaccines, recent identification of crucial stemne
231 , the king tapped Samir Khleif, chief of the cancer vaccine section at the US National Cancer Institu
232 results suggest that clinical protocols for cancer vaccines should be designed to avoid exposing res
234 servations, different DCs clinically used as cancer vaccines show different Treg-recruiting abilities
235 , in combination with a dendritic cell-based cancer vaccine significantly augments vaccine efficacy i
237 ssue-specific, and it offers a rationale for cancer vaccine strategies targeting tissue-restricted tu
238 opment of highly effective immunotherapeutic cancer vaccine strategies using engineered uracil auxotr
241 Ags by exosomes is under consideration as a cancer vaccine strategy; however, we found that pretreat
242 ere, we report the findings of a preclinical cancer vaccine study demonstrating vaccine-dependent PDL
244 umor phenotype may predict for resistance to cancer vaccines, suggesting a possible predictive biomar
251 ress has been made, but we do not yet have a cancer vaccine that can reliably and consistently induce
253 may lead to the development of optimal anti-cancer vaccines that can induce an orchestrated effort o
254 opment of a new class of recombinant protein cancer vaccines that deliver different CD8(+) and CD4(+)
255 nanoscale constructs as potential synthetic cancer vaccines that generate significant titers of anti
256 duction of an efficacious immune response by cancer vaccines that solely provide more antigen to an a
258 te the tremendous potential of peptide-based cancer vaccines, their efficacy has been limited in huma
263 ool for improving the potency of therapeutic cancer vaccines through the efficient induction of NK ce
266 nd, hence, may be useful to incorporate into cancer vaccines to enhance antitumor immunity against EB
267 cells needs to be considered when designing cancer vaccines to ensure full potential of the treatmen
268 lain the dissociation between the ability of cancer vaccines to induce high numbers of tumor-specific
270 rently being evaluated in clinical trials as cancer vaccines to induce tumor-specific immune response
271 , we can drive a concerted effort focused on cancer vaccines to reprogram the immune response to prev
272 ort the use of PD-1 and Tim-3 blockades with cancer vaccines to stimulate potent antitumor T-cell res
273 within a tumor will likely be necessary for cancer vaccines to trigger an effective antitumor respon
282 responses, our data provide a rationale for cancer vaccine trials with peptides derived from the NY-
285 be useful not only for immune monitoring of cancer vaccine trials, but also for adoptive cellular im
288 oth the onset and the monitoring of upcoming cancer-vaccine trials using SSX-derived immunogens.
290 to that achieved by a virotherapy-associated cancer vaccine using a recombinant oncolytic vaccinia vi
294 e potential of SOX-4 for broad use as a lung cancer vaccine, we have evaluated the expression of SOX-
295 -KLH are promising candidates as therapeutic cancer vaccines, whereas fully synthetic GM2-MPLA, which
296 attractive candidates for broadly applicable cancer vaccines, which could combine multiple tumor epit
297 l needed to determine the role that DC-based cancer vaccines will have, the most effective way to del
300 d in vivo for their potential as therapeutic cancer vaccines yielding promising therapeutic results f
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。